Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A class of highly selective inhibitors bind to an active state of PI3Kγ.
Gangadhara G, Dahl G, Bohnacker T, Rae R, Gunnarsson J, Blaho S, Öster L, Lindmark H, Karabelas K, Pemberton N, Tyrchan C, Mogemark M, Wymann MP, Williams RL, Perry MWD, Papavoine T, Petersen J. Gangadhara G, et al. Among authors: mogemark m. Nat Chem Biol. 2019 Apr;15(4):348-357. doi: 10.1038/s41589-018-0215-0. Epub 2019 Feb 4. Nat Chem Biol. 2019. PMID: 30718815
Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.
Pemberton N, Mogemark M, Arlbrandt S, Bold P, Cox RJ, Gardelli C, Holden NS, Karabelas K, Karlsson J, Lever S, Li X, Lindmark H, Norberg M, Perry MWD, Petersen J, Rodrigo Blomqvist S, Thomas M, Tyrchan C, Westin Eriksson A, Zlatoidsky P, Öster L. Pemberton N, et al. Among authors: mogemark m. J Med Chem. 2018 Jun 28;61(12):5435-5441. doi: 10.1021/acs.jmedchem.8b00447. Epub 2018 Jun 18. J Med Chem. 2018. PMID: 29852070
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma.
Perry MWD, Björhall K, Bold P, Brűlls M, Börjesson U, Carlsson J, Chang HA, Chen Y, Eriksson A, Fihn BM, Fransson R, Fredlund L, Ge H, Huang H, Karabelas K, Lamm Bergström E, Lever S, Lindmark H, Mogemark M, Nikitidis A, Palmgren AP, Pemberton N, Petersen J, Rodrigo Blomqvist M, Smith RW, Thomas MJ, Ullah V, Tyrchan C, Wennberg T, Westin Eriksson A, Yang W, Zhao S, Öster L. Perry MWD, et al. Among authors: mogemark m. J Med Chem. 2021 Jun 24;64(12):8053-8075. doi: 10.1021/acs.jmedchem.1c00434. Epub 2021 Jun 3. J Med Chem. 2021. PMID: 34080862
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
Ripa L, Sandmark J, Hughes G, Shamovsky I, Gunnarsson A, Johansson J, Llinas A, Collins M, Jung B, Novén A, Pemberton N, Mogemark M, Xiong Y, Li Q, Tångefjord S, Ek M, Åstrand A. Ripa L, et al. Among authors: mogemark m. J Med Chem. 2023 Oct 26;66(20):14188-14207. doi: 10.1021/acs.jmedchem.3c01269. Epub 2023 Oct 5. J Med Chem. 2023. PMID: 37797307
An Angle on MK2 Inhibition-Optimization and Evaluation of Prevention of Activation Inhibitors.
Hedström U, Norberg M, Evertsson E, Lever SR, Munck Af Rosenschöld M, Lönn H, Bold P, Käck H, Berntsson P, Vinblad J, Liu J, Welinder A, Karlsson J, Snijder A, Pardali K, Andersson U, Davis AM, Mogemark M. Hedström U, et al. Among authors: mogemark m. ChemMedChem. 2019 Oct 4;14(19):1701-1709. doi: 10.1002/cmdc.201900303. Epub 2019 Aug 13. ChemMedChem. 2019. PMID: 31325352
13 results